<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00446147</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-ONCGI-0403</org_study_id>
    <nct_id>NCT00446147</nct_id>
  </id_info>
  <brief_title>Study of Pyridoxine for Hand-Foot Syndrome</brief_title>
  <official_title>Double-Blind Phase III Study of Pyridoxine vs Placebo for the Prevention of Capecitabine-induced Hand-Foot Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although pyridoxine has been used empirically for the prevention of capecitabine associated
      hand-foot syndrome (HFS), its efficacy needs to be demonstrated in prospective controlled
      trials. The investigators therefore performed a prospective randomized double-blind study to
      determine whether pyridoxine 200 mg/day can prevent the development of HFS when given
      concurrently with capecitabine. The investigators also tested the ability of pyridoxine to
      treat primary occurrence of grade 2-3 HFS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although pyridoxine has been used empirically for the prevention of capecitabine associated
      HFS, its efficacy needs to be demonstrated in prospective controlled trials. We estimated
      that the HFS rate with placebo and pyridoxine would be 0.35 and 0.18, respectively, and we
      therefore calculated that a sample size of 345 patients would be necessary to detect these
      hazard rates with an 80% power (β=0.2) and two-sided significance level of α=0.05. We assumed
      a follow up loss rate of 10%, thus requiring 380 patients to be randomized.
      Chemotherapy-naive patients with gastrointestinal tract cancers who were scheduled for
      capecitabine-containing chemotherapy were assigned to receive oral pyridoxine or placebo in
      randomized double-blind placebo controlled study. Pyridoxine 100 mg b.i.d was prescribed to
      the patients in the pyridoxine group, identical placebo 100 mg b.i.d was prescribed in the
      placebo group by the closed envelop randomization. Patients were stratified by chemotherapy
      regimen: capecitabine alone (X), capecitabine and cisplatin (XP), or docetaxel, capecitabine,
      and cisplatin (DXP). Patients were observed until NCI CTC grade 2 or 3 HFS developed or
      capecitabine-containing chemotherapy ended. Patients in the placebo group who developed grade
      2 or 3 HFS were randomized to receive pyridoxine or placebo for the next chemotherapy cycle
      to determine whether pyridoxine could improve HFS, and the same treatment was continued for 2
      chemotherapy cycles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Dose of Capecitabine Until the Development of Grade 2 or Higher Hand-foot Syndrome</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>A total administered dose of capecitabine until the development of grade 2 or higher hand-foot syndrome during the chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Hand-foot Syndrome</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of patients with any grade of hand-foot syndrome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">389</enrollment>
  <condition>Hand-foot Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one tablet twice per day, which is identical to pyridoxine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pyridoxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg twice per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridoxine</intervention_name>
    <description>100mg BID/daily, Per oral</description>
    <arm_group_label>Pyridoxine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo 100mg BID/daily, Per oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gastrointestinal tract cancer patients treated with capecitabine-containing
             chemotherapy as a first-line treatment were randomly allocated to concurrent treatment
             with pyridoxine or placebo.

          -  All patients were 18 to 70 years old

          -  Had Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower

          -  An estimated life expectancy &gt; 3 months

          -  Adequate bone marrow function, including white blood cell (WBC) count of ＞3500 cells/㎕
             and platelet count of ＞100000/㎕

          -  Adequate renal function (serum creatinine concentration &lt;1.5 mg/㎗)

          -  Adequate liver function with (serum bilirubin concentration &lt;1.5 mg/㎗, transaminase &lt;3
             times the upper normal limit, and serum albumin ＞2.5 mg/㎗).

        Exclusion Criteria:

          -  Previous treatment for HFS

          -  Hypersensitivity to pyridoxine

          -  A combination of other malignancies

          -  Serious illnesses or medical conditions

          -  Immune suppression or positive human immunodeficiency virus (HIV) serology

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Koo Kang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center IRB</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2007</study_first_submitted>
  <study_first_submitted_qc>March 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2007</study_first_posted>
  <results_first_submitted>January 13, 2014</results_first_submitted>
  <results_first_submitted_qc>January 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2014</results_first_posted>
  <last_update_submitted>January 13, 2014</last_update_submitted>
  <last_update_submitted_qc>January 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Yoon-Koo Kang</investigator_full_name>
    <investigator_title>Oncologist</investigator_title>
  </responsible_party>
  <keyword>hand-foot syndrome</keyword>
  <keyword>capecitabine</keyword>
  <keyword>pyridoxine</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hand-Foot Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>one tablet twice per day, which is identical to pyridoxine
Placebo: placebo 100mg BID/daily, Per oral</description>
        </group>
        <group group_id="P2">
          <title>Pyridoxine</title>
          <description>100 mg twice per day
Pyridoxine: 100mg BID/daily, Per oral</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>one tablet twice per day, which is identical to pyridoxine
Placebo: placebo 100mg BID/daily, Per oral</description>
        </group>
        <group group_id="B2">
          <title>Pyridoxine</title>
          <description>100 mg twice per day
Pyridoxine: 100mg BID/daily, Per oral</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="180"/>
            <count group_id="B2" value="180"/>
            <count group_id="B3" value="360"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age_median</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="28" upper_limit="74"/>
                    <measurement group_id="B2" value="56" lower_limit="20" upper_limit="75"/>
                    <measurement group_id="B3" value="56" lower_limit="20" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Dose of Capecitabine Until the Development of Grade 2 or Higher Hand-foot Syndrome</title>
        <description>A total administered dose of capecitabine until the development of grade 2 or higher hand-foot syndrome during the chemotherapy.</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>one tablet twice per day, which is identical to pyridoxine
Placebo: placebo 100mg BID/daily, Per oral</description>
          </group>
          <group group_id="O2">
            <title>Pyridoxine</title>
            <description>100 mg twice per day
Pyridoxine: 100mg BID/daily, Per oral</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Dose of Capecitabine Until the Development of Grade 2 or Higher Hand-foot Syndrome</title>
          <description>A total administered dose of capecitabine until the development of grade 2 or higher hand-foot syndrome during the chemotherapy.</description>
          <units>miligram per square meter</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70000" lower_limit="69384" upper_limit="70615"/>
                    <measurement group_id="O2" value="70000" lower_limit="60010" upper_limit="79989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Hand-foot Syndrome</title>
        <description>Number of patients with any grade of hand-foot syndrome</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>one tablet twice per day, which is identical to pyridoxine
Placebo: placebo 100mg BID/daily, Per oral</description>
          </group>
          <group group_id="O2">
            <title>Pyridoxine</title>
            <description>100 mg twice per day
Pyridoxine: 100mg BID/daily, Per oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hand-foot Syndrome</title>
          <description>Number of patients with any grade of hand-foot syndrome</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>one tablet twice per day, which is identical to pyridoxine
Placebo: placebo 100mg BID/daily, Per oral</description>
        </group>
        <group group_id="E2">
          <title>Pyridoxine</title>
          <description>100 mg twice per day
Pyridoxine: 100mg BID/daily, Per oral</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yoon-Koo Kang</name_or_title>
      <organization>Asan Medical Center</organization>
      <phone>+82-2-3010-3210</phone>
      <email>ykkang@amc.seoul.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

